Goji Berry Extract and Alzheimer’s Disease: WNT/GSK3β Mechanism Study
🧠 Alzheimer’s Disease as a Multi-Pathology Neurodegenerative Network #
Alzheimer’s disease (AD) is characterized by interconnected pathological processes rather than a single molecular defect. Core features include amyloid-beta (Aβ) plaque accumulation, tau hyperphosphorylation, chronic neuroinflammation, synaptic failure, and progressive neuronal loss.
Beyond cognition, growing evidence highlights early involvement of the retina as part of a broader retina–brain axis. Retinal ganglion cell (RGC) loss, optic nerve fiber thinning, and visual processing deficits can precede or parallel central nervous system degeneration, suggesting AD is a system-wide neurodegenerative disorder.
Current pharmacological therapies, including cholinesterase inhibitors and NMDA receptor antagonists, primarily offer symptomatic relief and do not sufficiently address the multi-pathway nature of the disease.
🌿 Lycium barbarum Extract: A Multi-Component Neuroactive System #
Lycium barbarum (goji berry) contains structurally diverse bioactive compounds, including:
- Lycibarbarspermidines (acyl polyamines)
- Flavonoids such as rutin
- Lycium barbarum polysaccharides (LBP)
These compounds collectively exhibit antioxidant, anti-inflammatory, and neuroprotective activity, making the extract a candidate for multi-target intervention in neurodegenerative disease networks.
LC-MS profiling of Lycium barbarum aqueous extract (LBE) identifies a chemically heterogeneous composition with distinct functional classes, supporting the concept of systems-level pharmacology rather than single-target drug action.
🧬 Preclinical AD Model Design: 5xFAD and 3xTG Systems #
The study evaluates LBE in two established transgenic Alzheimer’s mouse models:
- 5xFAD model: Rapid amyloid-beta deposition and early cognitive decline
- 3xTG model: Combined amyloid-beta and tau pathology with progressive neurodegeneration
This dual-model design enables evaluation across both amyloid-driven and tau-driven disease mechanisms, reflecting the heterogeneity of human AD pathology.
🧪 Amyloid, Synaptic Function, and Visual Circuit Outcomes #
5xFAD model: amyloid burden and synaptic plasticity #
High-dose LBE administration reduced hippocampal Aβ plaque burden and improved long-term potentiation (LTP), indicating partial restoration of synaptic plasticity in affected circuits.
Electrophysiological data suggest improved neuronal network responsiveness, although behavioral cognitive recovery remained limited in advanced disease stages, consistent with irreversible network loss in late pathology.
Retina–brain axis effects #
Retinal ganglion cell activity increased following LBE treatment, accompanied by improvements in pattern electroretinogram (pERG) signals. These findings support the hypothesis that retinal circuits reflect central neurodegeneration and may respond to systemically active neuroprotective compounds.
🧠 Tau Pathology and Cognitive Circuit Recovery in 3xTG Mice #
In the 3xTG model, LBE demonstrated measurable effects on tau pathology:
- Reduced hippocampal phosphorylated tau (P-Tau) accumulation
- Improved spatial learning performance in Morris water maze testing
- Enhanced fear-associated memory retention in late-stage disease models
These effects suggest partial restoration of synaptic and network-level integrity in both hippocampal and cortical circuits.
👁️ Retinal Structural and Functional Restoration #
Retinal analyses show multi-layer neuroprotective effects:
- Increased retinal ganglion cell density (Brn3a labeling)
- Reduced microglial activation (Iba1 markers)
- Decreased oxidative stress (DHE assays)
- Improved light-evoked electrophysiological responses
These results indicate that LBE affects not only central brain pathology but also peripheral neural structures linked to visual processing.
🔬 Mechanistic Insight: WNT/KRAS/GSK3β–Tau Signaling Axis #
Transcriptomic and protein-level analyses identify the WNT signaling pathway as a key regulatory axis affected by LBE.
Core mechanistic pathway #
- Activation of WNT5a/b signaling
- Modulation of KRAS activity
- Inhibition of GSK3β kinase activity
- Reduction in tau phosphorylation (P-Tau)
:contentReference[oaicite:0]{index=0}
Downstream effects #
- Reduced tau aggregation
- Improved mitochondrial gene expression (Uqcrb, Cox20)
- Lower oxidative stress and inflammatory signaling
- Restoration of synaptic and neuronal energy balance
This positions LBE as a multi-target modulator operating across signaling, metabolic, and inflammatory domains rather than a single-pathway inhibitor.
🔄 Systems Biology Interpretation: Multi-Target Neuroprotection #
The combined data support a systems-level model of action:
- Amyloid reduction in early-stage pathology
- Tau modulation in mid-to-late stage disease
- Retinal circuit restoration linked to CNS signaling
- Mitochondrial and oxidative stress regulation as supporting mechanisms
This aligns with network pharmacology principles, where complex botanical extracts exert distributed effects across interconnected biological pathways.
🧩 Conclusion: Preclinical Evidence for Multi-Pathway AD Modulation #
This study provides preclinical evidence that Lycium barbarum extract may modulate multiple pathological axes in Alzheimer’s disease models, including amyloid burden, tau phosphorylation, synaptic plasticity, and retinal neurodegeneration.
Mechanistically, the WNT–KRAS–GSK3β signaling pathway emerges as a central regulatory node linking metabolic, inflammatory, and neurodegenerative processes.
While these findings are limited to animal models and do not imply clinical efficacy in humans, they highlight the potential of multi-component natural compounds as systems-level probes for complex neurodegenerative disease networks.